Last Updated on October 6, 2024 by The Health Master
The Department of Pharmaceuticals (DoP) has approved a6 applications i.e. 8 each under the production linked incentive (PLI) schemes—for bulk drugs and for medical devices – during the month of March, 2022, from the second round of application received for consideration.
The Department has approved an inflow of Rs. 1,172.06 crore of Foreign Direct Investment (FDI) allowing four out of the total 13 proposals in hand.
For the PLI scheme for bulk drugs, the second round has seen 24 applications coming to the Department, of which eight has been approved during the month.
In the first round, around 215 applications were received, of which 41 were approved by the DoP.
The department figures show that the total number of applications submitted for the Scheme for bulk drugs so far at 239, of which a total of 49 has been approved till the end of March, 2022.
Under the PLI scheme for medical devices, in the second round of invitation extended by the DoP, around 14 applications were received. In the month of March, more than half of them, around eight out of these 14 applications were approved by the Department.
Under the first round of the scheme, there were 28 applications, of which 13 has been approved. The total applications approved, out of the 42 applications received, stands at 21 at the end of March, 2022.
The PLI scheme for pharmaceuticals has a total of 55 applications approved out of the total 278 received till the end of March, added the monthly summary report released by the DoP on April 19, 2022.
The PLI scheme is aimed at promotion of domestic manufacturing of bulk drugs by setting up greenfield plants with minimum domestic value addition in four different target segment (in two fermentation based – at least 90 per cent and in two chemical synthesis based – at least 70 per cent) for 41 products with a total outlay of Rs. 6,940 crore, for the period of 2020-21 to 2029-30.
The DoP has issued guidelines for the PLI scheme for these drugs for the first time on October 29, 2020 and applications received in two rounds have already been appraised and selected.
For the initial round, the government has received 215 applications for the 36 products spread across the four target segments, out of which 42 applications were approved by the government with a total committed investment of Rs. 4,347.26 crore and expected employment generation of around 8,792 persons.
Since a few slots remained unfilled for certain products, a second round of applications were invited with the last date of submission as August 31, 2021 and a total of 24 applications were received.
The empowered committee on November 25, selected eight companies to set up plants with a committed investment of around Rs. 151.12 crore, and employment generation of around 1,951 persons. The commercial production of these plants are projected to commence from April 1, 2023 onwards.
The DoP also said in the monthly report that it has released Rs. 7.5 crore as third instalment of its commitment to the Andhra Pradesh Medtech Zone Ltd (AMTZ), under the sub-scheme of Assistance to Medical Device Industry for Common Facility Centre.
Under the sub-scheme, the DoP is expected to provide a one-time grant-in-aid of Rs. 25 crore or 70 per cent of the project cost, whichever is less, for creation of identified infrastructure and common facilities to a State Implementing Agency set up for the proposal. It has supported the proposal of AMTZ to provide grant-in-aid of Rs. 25 crore.
Under the Scheme for Promotion of Medical Devices Parks, it has released an amount of Rs. 30 crore as first instalment to the State governments of Tamil Nadu, Madhya Pradesh, Himachal Pradesh and Uttar Pradesh, it added.
The Department received two FDI proposals during the month of March, taking the total proposals pending with it to 13, of which four were disposed during the month. At the end of the month, there are nine proposals pending with the DoP.
Aurobindo, Sun Pharma recall products due to these reasons
IPGA Haryana organized a seminar to share knowledge for Pharma sector
Drug recall: Pfizer recalls some batches of Blood Pressure drug due…
NPPA panel rejects Cadila Healthcare’s application to fix retail price of…
SEC of DCGI asked Bharat Biotech to provide more data on Covaxin for children aged below 12
Govt working on policy to boost R&D in Pharma Sector
USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets
NPPA to set up digital platform to track availability of essential…
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
